Immunotherapy with monoclonal antibodies, such as antiprogrammed cell death protein 1 (PD-1) nivolumab, anticytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) ipilimumab, and anti lymphocyte activation gene 3 (LAG-3) relatlimab, modulated the immune responses in the tumor microenvironment and interfered with tumor growth and spread [106,107]. The gene discussed is CTLA4; the disease is neoplasm.